Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

The FDA approved a polypill containing telmisartan, amlodipine, and indapamide, known as Widaplik, for the treatment of hypertension in adults, including as initial treatment.

WIDAPLIK is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in ...

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025.

WIDAPLIK is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three ...

According to the notification issued by the Authority on February 7, 2025, the new retail price for the Cilnidipine & Telmisartan tablet (film-coated, 20mg/40mg) has been set at Rs14.15 per tablet.

It also covers the 325 mg and 500 mg doses of acetaminophen tablets. For the telmisartan, the recall includes the 40 mg and 80 mg pills.

The company's telmisartan 40 mg tablet and 80 mg tablets were also recalled. Telmisartan is typically used to treat mild to moderate high blood pressure or, in some cases, to reduce the risk of ...